These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17555372)

  • 1. The developing trend of monoclonal antibodies in the treatment of colorectal cancer.
    Elfiky AA; Saif MW
    Expert Opin Biol Ther; 2007 Jun; 7(6):871-83. PubMed ID: 17555372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological agents versus chemotherapy in the treatment of colorectal cancer.
    Eng C; Shalan N
    Expert Opin Pharmacother; 2006 Jul; 7(10):1251-71. PubMed ID: 16805714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies for targeted therapy in colorectal cancer.
    Banerjee S; Flores-Rozas H
    Cancer Biol Ther; 2010 Apr; 9(8):563-71. PubMed ID: 20200482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panitumumab a novel drug in cancer treatment.
    Cartenì G; Fiorentino R; Vecchione L; Chiurazzi B; Battista C
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi16-21. PubMed ID: 17591813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab in the treatment of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Expert Opin Biol Ther; 2007 Feb; 7(2):243-56. PubMed ID: 17250462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.
    Hohla F; Winder T; Greil R; Rick FG; Block NL; Schally AV
    World J Gastroenterol; 2014 May; 20(20):6102-12. PubMed ID: 24876732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma.
    Mellstedt H; Fagerberg J; Frödin JE; Hjelm-Skog AL; Liljefors M; Markovic K; Mosolits S; Ragnhammar P
    Ann N Y Acad Sci; 2000 Jun; 910():254-61; discussion 261-2. PubMed ID: 10911918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer.
    Wen F; Li Q
    World J Gastroenterol; 2016 Jun; 22(23):5332-41. PubMed ID: 27340349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy for metastatic colorectal cancer.
    Price TJ; Tang M; Gibbs P; Haller DG; Peeters M; Arnold D; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M; Shapiro J
    Expert Rev Anticancer Ther; 2018 Oct; 18(10):991-1006. PubMed ID: 30019590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab in the treatment of colorectal cancer.
    Cilley JC; Barfi K; Benson AB; Mulcahy MF
    Expert Opin Biol Ther; 2007 May; 7(5):739-49. PubMed ID: 17477810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular target therapy for colonic neoplasms].
    Oki E; Ota M; Honbo T; Egashira A; Tokunaga E; Sadanaga N; Morita M; Kakeji Y; Maehara Y
    Nihon Naika Gakkai Zasshi; 2007 Feb; 96(2):289-94. PubMed ID: 17370595
    [No Abstract]   [Full Text] [Related]  

  • 12. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies in the treatment of advanced colorectal cancer.
    Capdevila J; Saura C; Macarulla T; Casado E; Ramos FJ; Tabernero J
    Eur J Surg Oncol; 2007 Dec; 33 Suppl 2():S24-34. PubMed ID: 17981431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Patel DK
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
    Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
    Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms and targeting of colorectal cancer.
    Vanhoefer U
    Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer.
    De Pauw I; Wouters A; Van den Bossche J; Peeters M; Pauwels P; Deschoolmeester V; Vermorken JB; Lardon F
    Pharmacol Ther; 2016 Oct; 166():71-83. PubMed ID: 27373506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
    Saridaki Z; Georgoulias V; Souglakos J
    World J Gastroenterol; 2010 Mar; 16(10):1177-87. PubMed ID: 20222160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EpCAM: A new therapeutic target for an old cancer antigen.
    Armstrong A; Eck SL
    Cancer Biol Ther; 2003; 2(4):320-6. PubMed ID: 14508099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.